Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 3 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
2 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, Yesterday

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Decline in activities of daily living predicts HF hospitalization, death

18 Apr 2019

A decline in activities of daily living (ADL) appears to predict being hospitalized for heart failure (HF) and death in HF patients, a recent study suggests.

Drawing from the Kitakawachi Clinical Background and Outcome of Heart Failure Registry, researchers enrolled 923 HF patients (mean age, 75.7±11.2 years; 54.9 percent male). ADLs were categorized into four: independent outdoor walking, independent indoor walking, indoor walking with assistance and abasia. The primary study endpoint was hospitalization for HF.

Most of the patients (89.4 percent; n=825) did not show a decline in ADL while the remaining 10.6 percent (n=98) did. Over a median follow-up period of 369 days, 30.3 percent (n=279) of the participants were hospitalized for HF.

Analysis according to ADL status showed that there were more incidences of HF hospitalization in the group of patients with vs without ADL decline (46.4 percent vs 28.4 percent). This translated to a significantly higher risk of the primary outcome, as measured by multivariable Cox proportional hazard models (hazard ratio [HR], 1.89; 95 percent CI, 1.35–2.58; p<0.001).

Over the same time period, 12.9 percent (n=119) of the overall sample had died. Mortality was likewise more common in the ADL-decline group (28.9 percent vs 11 percent), resulting in a significantly greater risk (HR, 2.67; 1.71–4.02; p<0.001).

Moreover, in a multivariate analysis including all patients, a decline in ADL again emerged as a significant predictor of HF hospitalization (HR, 1.42; 1.01–1.96; p=0.046) and death (HR, 1.95; 1.23–2.99; p<0.01).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 3 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
2 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, Yesterday

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.